Arrivent BioPharma, Inc. (AVBP)
16.63
+0.17
(+1.03%)
USD |
NASDAQ |
Oct 13, 11:41
Arrivent BioPharma Shareholders Equity (Quarterly) : 366.84M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 366.84M |
| March 31, 2026 | 323.98M |
| December 31, 2025 | 307.22M |
| September 30, 2025 | 305.00M |
| June 30, 2025 | 249.87M |
| March 31, 2025 | 202.54M |
| December 31, 2024 | 257.65M |
| September 30, 2024 | 277.49M |
| Date | Value |
|---|---|
| June 30, 2024 | 296.66M |
| March 31, 2024 | 317.72M |
| December 31, 2023 | 151.30M |
| September 30, 2023 | 171.99M |
| June 30, 2023 | 186.03M |
| March 31, 2023 | |
| December 31, 2022 | 174.46M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 394.72M |
| Total Liabilities (Quarterly) | 27.88M |
| Debt to Equity Ratio | 0.001 |
| Current Ratio | 14.16 |
| Net Debt Paydown Yield | 0.00% |